TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Tonix Pharmaceuticals Holding Corp.

509 Madison Avenue
Suite 306
New York, NY 10022
United States
212-980-9155
http://www.tonixpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Dr. Seth LedermanCo-Founder, Pres, CEO & Chairman472.5kN/A1958
Mr. Bradley SaengerCFO & Treasurer335kN/A1974
Dr. Gregory M. SullivanChief Medical Officer & Sec.335kN/A1966
Mrs. Jessica Edgar MorrisChief Operating OfficerN/AN/AN/A
Dr. Ronald R. Notvest Ph.D., MBAExec. VP of Commercial Planning and Devel.N/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

Corporate Governance

Tonix Pharmaceuticals Holding Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.